Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 085 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx se xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 o xxxxxxxxxxx, označování x xxxxxx xxxxx a xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx na Smlouvu x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem na xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx x směsí, x změně a xxxxxxx směrnic 67/548/EHS x 1999/45/ES x x změně nařízení (XX) x. 1907/2006 (1), x xxxxxxx xx xx. 37 xxxx. 5 xxxxxxxxx nařízení,

vzhledem x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x části 3 přílohy VI xxxxxxxx (XX) č. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx látek xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx látky („xxxxxxxx“) xxxx v souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 předloženy návrhy xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx a xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx i xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx zavést, aktualizovat xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx látek. Xxxxxxx xxxxxxxxxx xxxxxx XXX xxxx:

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx xx dne 9. března 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx a xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně granulované xxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] stannanu, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx dibenzo[def,p]chrysenu, dibenzo[a,l]pyrenu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [K-HDO],

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx ze xxx 30. listopadu 2018 ohledně 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. října 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (XXX), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,

—

stanovisko xx dne 9. xxxxxx 2018 ohledně xxxxxxx, xxxxxxx [xxxx xxxxxxxx za xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (E)-2-{2-[6-(2-kyanofenoxy)pyrimidin-4-yloxy]fenyl}-3-methoxyakrylátu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx hymexazolu (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně hexythiazoxu (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx ze xxx 9. března 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx x látku xxxxx (číslo CAS 7439–92–1 a indexová xxxxx 082–013–00–1 (olovo x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), RAC xx xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx i xxxxxxxxx xxxxx. Avšak xxxxxxxx x nižší xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, xx xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x vzhledem k xxxxx xxxxxxxxxxxxxxx klasifikaci x xxxxxxxxxx a xxxxxxxxxx xxxxx jiných xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX xxxx RAC xxxxxxx xxxxx posouzení xxxx, zda xx xxx xx xxxxxxxxx x práškovou formu xxxxx použita xxxxxx xxxxxxxxxxxxxxx klasifikace. Xxxxx xxxx xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, x nichž xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx celistvou xxxxx, xxx xx xxxxxxxxxx xxxxxxxxxx xxxxxx RAC, xxxxxx xxx vhodná. Xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx VI xxxxxxxx (XX) x. 1272/2008, xxxxx RAC xxxxxx xxx možnost xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx jde x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly předloženy xxxx xxxxxxx poznatky, xx xxxxxxx vyplývá, xx klasifikace pro xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx RAC, xxx xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx vhodná. Tato xxxxx nebezpečnosti xx xxxxx xxxxxx xxx x příloze XX xxxxxxxx (ES) č. 1272/2008 xxxxxxx, dokud XXX nebude xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx XXX, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (ES) č. 1272/2008 xx proto xxxx xxx odpovídajícím xxxxxxxx změněno.

(6)

Dodržování nových xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, s xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx na xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx látek x xxxxx novým xxxx xxxxxxxxxxx klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Tato doba xx rovněž nezbytná x xxxx, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx xxxxxxxx xxxxx x zajištění xxxxxxxx dodržování xxxxxxx xxxxxxxx požadavků, xxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx nařízení. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx stanovené v xx. 22 odst. 1 xxxx. f) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (3) nebo xxxxxxxxx stanovené x xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx být umožněno, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx dnem xxxxxxxxxxxxx xxxxxx nařízení. To xx x xxxxxxx x xxxxxxxxx xxxxx xx. 61 xxxx. 2 nařízení (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx nařízení (XX) x. 1272/2008

Tabulka 3 v xxxxx 3 přílohy VI xxxxxxxx (XX) č. 1272/2008 xx xxxx x souladu s xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx x použitelnost

Toto xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx vyhlášení v Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx xx xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx být látky x směsi xxxxxxxxxxxxx, xxxxxxxxxx x xxxxxx x xxxxxxx x xxxxxxxxx (ES) x. 1272/2008 xx xxxxx xxxxxx nařízení ještě xxxxx xxxx 1. xxxxxx 2022.

Xxxx xxxxxxxx je xxxxxxx v xxxxx xxxxxxx a přímo xxxxxxxxxx xx všech xxxxxxxxx státech.

V Xxxxxxx xxx 19. xxxxxx 2020.

Xx Komisi

Ursula VON XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx této xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx parlamentu a Xxxx (ES) x. 1907/2006 ze xxx 18. xxxxxxxx 2006

o xxxxxxxxxx, hodnocení, povolování x omezování chemických xxxxx, x zřízení Xxxxxxxx agentury xxx xxxxxxxx látky, o xxxxx směrnice 1999/45/XX x x zrušení xxxxxxxx Xxxx (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Rady 76/769/XXX x xxxxxxx Xxxxxx 91/155/EHS, 93/67/EHS, 93/105/XX x 2000/21/ES (Xx. xxxx. L 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Xxxx (EU) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x jejich xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 se tabulka 3 x xxxxx 3 xxxx takto:

1)

Vkládají xx tyto xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a xxxxxxxxxx slov

Kódy xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. standardních xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx xxxxxxx …% [C ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 mg/l (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Skin Xxxx. 1X; H314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x karbidu křemíku (x xxxxxxx &xx; 3 μx, xxxxx &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Sens. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Liq. 2

Xxxxx Xxx. 3

Acute Xxx. 3

XXXX SE 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx cesty, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 mg/l (xxxx)

xxxxxx: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 mm; xxxxx xxxxxx: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

stannan, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1B

STOT XX 1

X360X

X372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

H350

H341

GHS08

Dgr

H350

H341

Carc. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxxxx 1

X360X

X302

X373 (oči, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 mg/kg XX

X = 100“

„603-238-00-9

bis(2-(2-methoxyethoxy)ethyl)-ether; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Acute Xxx. 4

Xxxxx Xxx. 4

Xxx Irrit. 2

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

X = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Xxx. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx XX

X = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

STOT RE 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg XX

X = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (ISO);

methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylát

–

317815-83-1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Acute Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová kyselina …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

STOT XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (xxxxx xxxx mlha)

orální: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

XXXX RE 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Aquatic Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2RS)-2-[4-(4-chlorfenoxy)-2-(trifluormethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;

mefentriflukonazol

–

1417782-03-6

Skin Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

XXXX XX 1

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: ATE = 0,14 xx/x (xxxxx nebo mlha)

orální: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 xx/xx TH

M = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Xxx. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 mg/l (xxxxx nebo xxxx)

xxxxxx: XXX = 567 xx/xx TH

Skin Xxxxx. 2; X315: 0,025 % ≤ C &xx; 5 %

Eye Xxxxx. 2; X319: 0,025 % ≤ X < 3 %

Xxxx Xxxx. 1 X; H317: C ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Tox. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Dam. 1

Skin Xxxx. 1 A

Aquatic Xxxxx 1

Aquatic Chronic 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx TH

Skin Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1B

Muta. 1X

XXXX XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamát

–

140923-17-7

Carc. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, výtažek [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Azadirachta xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx oxidem uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

X412

X412“

2)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X se xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy doplň. xxxxxxxxxxxx vět o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Ox. Xxx. 3; H272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

STOT XX 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 X: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach nebo xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx systém)

H410“

„082-013-00-1

olověný xxxxxx; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Tox. 4*

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Irrit. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

H350

H341

H311

H302

H315

H319

H317

H412

GHS08

GHS06

Dgr

H350

H341

H311

H302

H315

H319

H317

H412

dermální: XXX = 300 mg/kg XX orální: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT RE 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

azoxystrobin (ISO);

methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

M = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Acute Xxx. 3

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H361d

H373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

M = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [OIT]

247-761-7

26530-20-1

Acute Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: ATE = 311 mg/kg TH xxxxxx: ATE = 125 mg/kg XX

Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 xx/xx TH“

„613-125-00-6

hexythiazox (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; orální, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (prach nebo xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; ethylmethylketoxim, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

STOT SE 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (horní xxxxxxx cesty)

H373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní dýchací xxxxx)

X373 (krevní oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx XX xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 se xxxxxxx.